Home - Organovo, Inc.
WEBOrganovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease. Read More ». May 14 | 2024.
News & Events - Organovo, Inc.
WEBNews & Events - Organovo, Inc. Upcoming Events. There are no upcoming events at this time. Recent Press Releases. Jul 16, 2024. Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis. May 21, 2024.
Organovo Holdings, Inc. (ONVO) Latest Stock News & Headlines
WEBGet the latest Organovo Holdings, Inc. (ONVO) stock news and headlines to help you in your trading and investing decisions.
ONVO News Today | Why did Organovo stock go up today?
WEBSep 13, 2024 · What's going on at Organovo (NASDAQ:ONVO)? Read today's ONVO news from trusted media outlets at MarketBeat.
Organovo Holdings, Inc. (ONVO) Stock Price, News, Quote
WEBFind the latest Organovo Holdings, Inc. (ONVO) stock quote, history, news and other vital information to help you with your stock trading and investing.
Press Releases - Organovo Holdings, Inc.
WEBJul 16, 2024 · Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering. Apr 15, 2024. Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo. Jan 25, 2024.
Organovo Announces Positive Phase 2 Results for FXR314 in …
WEBApr 15, 2024 · Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability ...
Organovo Announces FXR Program | Organovo Holdings, Inc.
WEBMar 21, 2023 · Organovo’s FXR program announcement updates its previous guidance that it would first begin Phase 1 trials in 2025. The Company plans to give guidance on Phase 2 timelines after an internal determination of the best path forward.
Organovo Highlights FXR314 Near Term Value Catalysts at
WEBSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
Bioprinting Battle Ends: BICO and Organovo Come to Licensing …
WEBMar 4, 2022 · Upon news of the deal, Organovo stock jumped 49.7 percent. In 2021, the two bioprinting firms were involved in several legal disputes, with BICO, formerly Cellink, making a sealed complaint...
- Some results have been removed
Skip to content